GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMOP.PFD) » Definitions » EV-to-FCF

CDMOP.PFD (Avid Bioservices) EV-to-FCF : 3.64 (As of Jun. 29, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Avid Bioservices EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Avid Bioservices's Enterprise Value is $-35.20 Mil. Avid Bioservices's Free Cash Flow for the trailing twelve months (TTM) ended in Oct. 2024 was $-9.68 Mil. Therefore, Avid Bioservices's EV-to-FCF for today is 3.64.

The historical rank and industry rank for Avid Bioservices's EV-to-FCF or its related term are showing as below:

CDMOP.PFD' s EV-to-FCF Range Over the Past 10 Years
Min: -154.29   Med: -3.8   Max: 274.01
Current: -100.3

During the past 13 years, the highest EV-to-FCF of Avid Bioservices was 274.01. The lowest was -154.29. And the median was -3.80.

CDMOP.PFD's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 6.27 vs CDMOP.PFD: -100.30

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-06-29), Avid Bioservices's stock price is $25.0602. Avid Bioservices's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2024 was $0.000. Therefore, Avid Bioservices's PE Ratio (TTM) for today is N/A.


Avid Bioservices EV-to-FCF Historical Data

The historical data trend for Avid Bioservices's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices EV-to-FCF Chart

Avid Bioservices Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 166.32 58.89 -18.92 -14.16 -31.33

Avid Bioservices Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.88 -15.43 -31.33 -73.22 -83.58

Competitive Comparison of Avid Bioservices's EV-to-FCF

For the Biotechnology subindustry, Avid Bioservices's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avid Bioservices's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avid Bioservices's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Avid Bioservices's EV-to-FCF falls into.


;
;

Avid Bioservices EV-to-FCF Calculation

Avid Bioservices's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-35.204/-9.681
=3.64

Avid Bioservices's current Enterprise Value is $-35.20 Mil.
Avid Bioservices's Free Cash Flow for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avid Bioservices  (NAS:CDMOP.PFD) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Avid Bioservices's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=25.0602/0.000
=N/A

Avid Bioservices's share price for today is $25.0602.
Avid Bioservices's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Avid Bioservices EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Avid Bioservices Business Description

Traded in Other Exchanges
N/A
Address
14191 Myford Road, Tustin, CA, USA, 92780
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.